Disparities in Wait-List Outcomes for Adults With Congenital Heart Disease Listed for Heart Transplantation Before and Since Revision of Status I Listing
Laith Alshawabkeh(UC San Diego Health System), Heather L. Bartlett(University of Wisconsin–Madison), Michael J. Landzberg(Boston Children's Hospital), Alexander R. Opotowsky(Cincinnati Children's Hospital Medical Center), Michael M. Givertz(Brigham and Women's Hospital), Marcus A. Urey(University of California San Diego), Knute D. Carter(University of Iowa)
Cited by 6
Related Papers
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
|New England Journal of Medicine|2000|908
Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair
|Heart|2006|492
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction
|Circulation|2019|427
Transplantation Outcomes with Donor Hearts after Circulatory Death
|New England Journal of Medicine|2023|328